

Case report

Open Access

Gastric T-cell lymphoma associated with hemophagocytic syndrome

Rika Fukui*¹, Fumitake Hata¹, Takahiro Yasoshima^{1,4}, Ryuuichi Denno¹, Minoru Okazaki¹, Kiyoshi Kasai², Masaaki Sato³, Toshio Homma¹, Keisuke Ohno¹, Yoshiyuki Yanai¹, Katsuya Sogahata¹, Hidefumi Nishimori¹ and Koichi Hirata¹

Address: ¹First Department of Surgery, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo 060-8543, Japan, ²First Department of Pathology, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo 060-8543, Japan, ³Department of Clinical Pathology, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo 060-8543, Japan and ⁴Department of Surgery, Shinsapporo Keiaikai Hospital, East-5, Ooyachi higashi, Atsubetsu-ku, Sapporo 004-0041, Japan

Email: Rika Fukui* - rfukui@sapmed.ac.jp; Fumitake Hata - fhata@sapmed.ac.jp; Takahiro Yasoshima - yasoshima@mtf.biglobe.ne.jp; Ryuuichi Denno - denno@sapmed.ac.jp; Minoru Okazaki - rfukui@sapmed.ac.jp; Kiyoshi Kasai - rfukui@sapmed.ac.jp; Masaaki Sato - rfukui@sapmed.ac.jp; Toshio Homma - rfukui@sapmed.ac.jp; Keisuke Ohno - oonok@sapmed.ac.jp; Yoshiyuki Yanai - rt1@koushin.or.jp; Katsuya Sogahata - rfukui@sapmed.ac.jp; Hidefumi Nishimori - rfukui@sapmed.ac.jp; Koichi Hirata - rfukui@sapmed.ac.jp

* Corresponding author

Published: 19 October 2004

Received: 01 June 2004

World Journal of Surgical Oncology 2004, 2:34 doi:10.1186/1477-7819-2-34

Accepted: 19 October 2004

This article is available from: <http://www.wjso.com/content/2/1/34>

© 2004 Fukui et al; licensee BioMed Central Ltd.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Lymphoma-associated hemophagocytic syndrome (LAHS) occurs in mostly extra nodal non-Hodgkin's lymphoma. LAHS arising from gastrointestinal lymphoma has never been reported. Here we report a case of gastric T-cell lymphoma-associated hemophagocytic syndrome.

Case presentation: A 51-year-old woman presented with pain, redness of breasts, fever and hematemesis. Hematological examination revealed anemia. Gastroscopy revealed small bleeding ulcers in the stomach and the computed tomography scan showed liver tumor. She underwent total gastrectomy for gastrointestinal bleeding and the histopathology revealed gastric T-cell lymphoma. She continued to bleed from the anastomosis and died on the 8th postoperative day. Autopsy revealed it to be a LAHS.

Conclusions: If Hemophagocytic syndrome (HPS) occurs in lymphoma of the gastrointestinal tract, bleeding from the primary lesion might be uncontrollable. Early diagnosis and appropriate treatment are needed for long-term survival.

Background

Hemophagocytic syndrome (HPS) in adults is characterized by reactive and systemic proliferation of benign histiocytes that phagocytose blood cells [1]. It is often associated with infections, malignant neoplasms, autoim-

mune diseases and various immunodeficiencies. Lymphoma-associated hemophagocytic syndrome (LAHS) mostly occurs from extra nodal lymphoma and is known to have a poor prognosis. Here we report a case of LAHS




Figure 1
Photomicrograph showing medium-large sized atypical lymphoid cells with pleomorphic features in the stomach suggesting a gastric lymphoma (Hematoxylin and Eosin, ×170).




Figure 2
Photomicrograph of the lymph node at autopsy illustrating histiocytes that show hemophagocytosis of normoblast in a lymph node (Hematoxylin and Eosin, ×200).

arising from gastric lymphoma with a fulminant clinical course and difficult diagnosis until the time of autopsy.

Case presentation

A 51-year-old female was admitted on May 9, 1995, because of severe hematemesis. The patient had been treated elsewhere for one month for pain and redness of both breasts and fever ($\geq 38^\circ\text{C}$). There was no generalized lymphadenopathy. On gastroscopic examination multiple small ulcers were observed in the stomach. An abdominal computed tomographic (CT) scan showed liver tumor and a normal spleen. Hematological and biochemical examination at admission showed the following results: RBC $352 \times 10^4/\text{mm}^3$, hemoglobin 10.3 g/dl (post transfusion), WBC $4,900/\text{mm}^3$, Platelets $51,000/\text{mm}^3$, serum albumin 1.5 g/dl, total bilirubin 0.6 mg/dl, AST 691 IU/l, ALT 187 IU/l, LDH 2976 IU/l, fibrinogen 134 mg/dl, FDP 10 $\mu\text{g}/\text{ml}$, and AT-III 40%. Bleeding from the stomach continued and did not stop with conservative treatment; therefore, two days later the patient underwent total gastrectomy and a partial liver resection. Histopathology of the resected specimen showed it to be a gastric lymphoma (pleomorphic medium-large cell type, non-Hodgkin's T-cell lymphoma) with liver metastasis (Fig. 1). From first postoperative day (POD), bleeding from the esophagojejunostomy continued; the patient developed disseminated intravascular coagulopathy and died on 8th postoperative day.

On autopsy, malignant lymphoid cell infiltration and hemophagocytosis were observed in the liver, spleen, heart, small bowel, lung, both breasts, kidney, pancreas, uterus, and gastroduodenal lymph nodes (Fig. 2). The

bone marrow presented hyperplasia and hemophagocytic macrophages but no infiltration by lymphoma cells. Immunohistochemically the neoplastic cells were positive for T-cell marker UCHL1 (CD45RO) and EBV by EBER *in situ* hybridization. The final diagnosis was EBV-related T-cell LAHS.

Discussion

HPS is a clinicopathological entity characterized by systemic proliferation of benign hemophagocytic histiocytes, fever, cytopenia, liver dysfunction, hepatosplenomegaly, and coagulopathy [1]. This syndrome has been observed during the clinical course of a wide variety of disorders, including viral infections and malignant neoplasms. Diagnostic guidelines of Henter *et al*, [2] are widely used for the diagnosis of HPS. However, these guidelines are not satisfactory in diagnosing HPS in adults; therefore, a number of studies on adult HPS have used their own criteria [1,3,4]. On the other hand for the diagnosis of LAHS, in addition to the clinical features, it is also important to confirm the presence of malignant lymphoid cells histopathologically. Takahashi *et al*, [5] has proposed a set of new diagnostic criteria for adult LAHS that has been detailed in Table 1.

In Japan, T-cell LAHS accounts for 48.5% of all adult LAHS [5]. T-cell LAHS mostly occurs in extra nodal, especially nasal, cutaneous, or malignant lymphoma involving liver and spleen. There have been no reports on LAHS from gastric lymphoma. As the diagnosis in the present case was made at autopsy it is not clear as to when the HPS occurred initially. One possibility is the setting of disseminated T-cell lymphoma. This is supported by the patient's

Table 1: Diagnostic criteria for adult lymphoma associates hemophagocytic syndrome (LAHS)

1 High fever for more than a week (peak 38.5°C)
2 Anemia (Hb < 9 g/dl) or thrombocytopenia (platelet < 100,000 μ /l)
3 a) LDH \geq 2 \times upper limit
b) Hyperferritinemia (\geq 1,000 ng/dl)
c) Hepatosplenomegaly on CT, US or MRI
d) FDP \geq 10 μ g/ml
4 Hemophagocytosis in bone marrow, spleen or liver
5 No evidence of infection
6 Histopathologically confirmed malignant lymphoma

- A diagnosis of LAHS requires that all of the above conditions are fulfilled.
- Of the item 3, at least two of the four sub-items (a~d) should be fulfilled.
- When item 1 to item 5 are present for 2 weeks and glucocorticoid or γ -globulin therapy is not effective, a diagnosis of probable LAHS can be made and chemotherapy against malignant lymphoma can be started.

fever, which continued for one month, liver dysfunction, and coagulopathy, which existed from the initial stage of the disease, however the bone marrow did not show any lymphoma infiltration. It could also be considered that the hemophagocytic syndrome occurred as a result of the surgery as pancytopenia and hepatosplenomegaly were not observed before the operation and hemophagocytosis was not recognized on histopathological examination in the resected stomach. In T-cell lymphoma, the hemophagocytic syndrome is assumed to be caused by cytokines, especially, tumor necrosis factor- α , and interferon- γ released from neoplastic T-cells [4,6]. Uncontrolled secretion of cytokines may stimulate the proliferation and phagocytic activity of macrophages. It seems likely that hypercytokinemia due to surgical resection might have contribute to the development of HPS in the present case. In our opinion the former is more likely however based on the findings of this case the second hypothesis too cannot be rejected.

The poor prognosis of LAHS, especially T-LAHS, is well known. The median survival time from the diagnosis is reported to be 143 and 69 days respectively in Japan [5]. For LAHS prompt initiation of treatment with multi agent chemotherapy is required to improve the symptoms and survival [7]. Bone marrow transplantation is considered to be a treatment for chemotherapy-resistant LAHS [8]. The median survival time of LAHS patients without chemotherapy is only 11 days [5].

In this case, the initial presentation was mastalgia and hence it took a considerable amount of time to reach a diagnosis. Furthermore, bleeding from the anastomosis continued leading to a rapidly progressive fatal clinical course.

In HPS occurring in lymphoma of the gastrointestinal tract uncontrollable bleeding from the primary lesion

might occur. Therefore, an earlier diagnosis of HPS should be made by bone marrow aspirates, and appropriate treatments should be started as soon as possible. Surgery if performed, must be performed with utmost caution.

Conclusions

LAHS could also occur from lymphoma of the gastrointestinal tract. For long-term survival; early diagnosis and appropriate treatment are needed. Surgery if performed without a proper diagnosis could prove fatal.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

RF, FH, TY, RD, KO and KH were gastrointestinal surgeons.

MO referred this patient to us.

KK and MS performed pathological examination and the autopsy.

KS was a member of the intensive care team.

TH, YY, HN gave us helpful comments about the manuscript

Acknowledgements

Permission of patient's relatives was obtained for publication of her case records

References

1. Wong KF, Chan JKC: **Reactive hemophagocytic syndrome-A clinicopathologic study of 40 patients in an Oriental population.** *Am J Med* 1992, **93**:177-180.
2. Henter JL, Elinder G, Ost A, and the FHL study group of the histiocyte society: **Diagnostic guidelines for hemophagocytic lymphohistiocytosis.** *Semin Oncol* 1991, **18**:29-33.

3. Yao M, Cheng AL, Su JJ, Lin MT, Uen WC, Tien HF, Wang CH, Chen YC: **Clinicopathological spectrum of haemophagocytic syndrome in Epstein-Barr virus-associated peripheral T-cell lymphoma.** *Br J Haematol* 1994, **87**:535-543.
4. Tsuda H: **Hemophagocytic syndrome in children and adults.** *Int J Hematol* 1997, **65**:215-226.
5. Takahashi N, Chubachi A, Miura I, Nakamura S, Miura BA: **Lymphoma associated hemophagocytic syndrome in Japan [Japanese].** *Jpn J Clin Hematol* 1999, **40**:542-549.
6. Lay JD, Tsao CJ, Chen JY, Kadin ME, Su JJ: **Upregulation of tumor necrosis factor- α gene by Epstein-Barr Virus and activation of macrophages in Epstein-Barr Virus-infected T cells in the pathogenesis of hemophagocytic syndrome.** *J Clin Invest* 1997, **100**:1969-1979.
7. Imasyuku S: **Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment.** *Int J Hematol* 1997, **66**:135-151.
8. Hasegawa D, Sano K, Kosaka Y, Hayakawa A, Nakamura H: **A case of hemophagocytic lymphohistiocytosis with prolonged remission after syngeneic bone marrow transplantation.** *Bone Marrow Transplant* 1999, **24**:425-427.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

